Laboratory chemistry Apolda

What Laboratory chemistry Apolda does

Laborchemie Apolda GmbH is a German cGMP-certified manufacturer of active pharmaceutical ingredients (APIs) and specialty chemicals, founded in 1949 in Apolda, Thuringia, and operating since 1993 as a 100% subsidiary of the HEYL Chemisch-pharmazeutische Fabrik group (Berlin). The company produces a portfolio of 10+ API products under cGMP, including D-Penicillamine (where it supplies approximately 70% of global demand for Wilson's disease treatment), Prussian blue, Chlorobutanol (anhydrous and hemihydrate), Sodium-DMPS, Propiverine-Hydrochloride, Methantheline bromide, and Butetamate, alongside specialty chemicals such as the Flavognost and Kalignost reagents and liquid crystal intermediates from a long-standing MERCK KGaA alliance. Manufacturing is concentrated in a single multi-purpose facility in Apolda equipped with reactor systems ranging from 30L glass to 3,200L glass-lined and stainless steel, high-vacuum distillation below 1 mbar, cryogenic and high-temperature processing (-25°C to +160°C), hydrogenation up to 6 bar, and capabilities for handling hazardous chemicals including H2S, POCl3, PCl3, and TiCl4, with advanced analytical instrumentation (Bruker GC-MS, UHPLC-Q-TOF, ReactIR FTIR) and a newly added HPAPI cleanroom.

The company operates a B2B direct sales model with quote-based custom synthesis pricing, targeting pharmaceutical and chemical industry customers worldwide. Revenue is generated through custom synthesis contracts, API supply agreements, process development and optimization services, and Drug Master File (DMF) compilation for regulatory authorities in the US (FDA), EU, Japan (MHLW), and Korea (KFDA). The customer base is anchored by the HEYL Group ecosystem (HEYL Berlin as the parent and primary finished-dose customer, plus Heyltex Corporation in the USA and HEYL Japan for RADIOGARDASE distribution), with MERCK KGaA as a major specialty chemicals customer for liquid crystal intermediates. Distribution is conducted directly under GDP (Good Distribution Practice) guidelines via logistics partners, with no e-commerce or marketplace channels. The company has accumulated five successful FDA audits since 2002 and more than 60 total audits since 2010, anchoring its compliance credentials across regulated markets.

Financially, Laborchemie reported approximately EUR 15 million in revenue for 2020 with roughly 10% year-over-year growth. Following a brief 2014 insolvency and 2015 restructuring, the company executed a EUR 2 million factory expansion in 2021 and committed a further EUR 3 million to the existing facility, with D-Penicillamine mass production launched in Q2 2022 at the new HPAPI cleanroom. The business is privately held with no external venture capital or institutional investment. Operational efficiencies include 60% solvent recycling via distillation, 70% emission reduction from activated carbon adsorber renewal, and 80% lighting electricity savings, supported by ISO 9001:2015, ISO 14001:2015, and ISO 50001:2018 certifications.

Name

Laboratory chemistry Apolda

Legal name

Laborchemie Apolda GmbH

Website

https://laborchemie.de

Company type

Private

Founded year

1949

Operating status

Operating

Headcount range

11–50 employees

Short description

Laborchemie Apolda GmbH is a German cGMP-certified manufacturer of active pharmaceutical ingredients and specialty chemicals, supplying approximately 70% of global D-Penicillamine demand for Wilson's disease and serving pharmaceutical and chemical industry clients globally.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredient (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Other Basic Organic Chemical Manufacturing (32519)

SIC

Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

Keywords

• Active pharmaceutical ingredients
• CGMP contract manufacturing
• Specialty chemicals
• Custom synthesis services
• Pharmaceutical intermediates

Headquarters

HQ city

Apolda

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure

Revenue model

1. Custom Synthesis of APIs: Contract manufacturing of pharmaceutical active ingredients under cGMP conditions for pharmaceutical industry clients. Revenue is generated through custom synthesis project fees and long-term supply contracts with pharmaceutical companies. API products include D-Penicillamin, Prussian blue, Sodium-DMPS, Chlorobutanol, Methantheline bromide, Propiverine-Hydrochloride, Butetamate, Menglytate, and others.
2. Specialty Chemicals Manufacturing: Custom manufacturing of specialty chemicals including liquid crystal substances, analytical reagents (Flavognost, Kalignost), and technical chemicals for industrial customers. Includes both cGMP and non-cGMP production.
3. Process Development and Optimization Services: Optimization of existing production processes and development of new synthesis routes from idea to final product, including analytical development, regulatory support (Drug Master Files), and scale-up.
4. Regulatory and Analytical Services: Compilation of Drug Master Files (DMF) for European and international authorities (USA, Japan, Poland, Spain, Portugal); analytical development including impurity identification and isolation.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Laborchemie Apolda GmbH is a cGMP-certified contract manufacturer of active pharmaceutical ingredients (APIs) and specialty chemicals, including liquid crystal substances and analytical reagents. The company manufactures APIs such as D-Penicillamine, Prussian blue, Sodium-DMPS, Propiverine-Hydrochloride, Methantheline bromide, Chlorobutanol, Menglytate, Butetamate, and α-Bromoisovaleric acid ethyl ester, alongside specialty chemicals such as Flavognost and Kalignost. It also offers custom synthesis, process development and scale-up, analytical development, and Drug Master File (DMF) compilation services for pharmaceutical and chemical industry clients.

Product overview

Laborchemie Apolda is a pharmaceutical and specialty chemical manufacturer operating as a 100% subsidiary of HEYL Chemisch-pharmazeutische Fabrik in Berlin. The company operates as a single unified production facility with integrated services. Their product portfolio consists of two main categories: (1) Active Pharmaceutical Ingredients (APIs) including Prussian blue (Berliner Blau), D-Penicillamine, α-Bromoisovaleric Acid Ethyl Ester, Butetamate-dihydrogencitrate, Chlorobutanol (anhydrous and hemihydrate), Menglytate, Methantheline bromide, Sodium-DMPS, and Propiverine-Hydrochloride, all manufactured under cGMP conditions; and (2) Specialty Chemicals including Flavognost® and Kalignost® reagents. The company also produces liquid crystal substances and intermediates. Supporting services include process development and optimization, custom synthesis, analytical development, regulatory services (DMF compilation), and logistics distribution under GDP guidelines. The company operates from a single production facility in Apolda, Germany, combining modular and multi-purpose equipment for manufacturing from laboratory scale to small-ton scale production.

Differentiator

Problem solved

Functional benefit

Products and services

• Prussian blue (Berliner Blau) Iron(III)-hexacyanoferrate(II) x H2O API used for the treatment of Wilson's disease (Morbus Wilson) and as the active ingredient for RADIOGARDASE, an antidote for radioactive cesium and thallium poisoning. Laborchemie Apolda produces approximately 70% of the world market demand for this API.
• D-Penicillamine (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid (CAS 52-67-5, molecular weight 149.21 g/mol), an API used for Wilson's disease (Morbus Wilson) treatment. Mass production started in Q2 2022 in a new cleanroom facility.
• α-Bromoisovaleric Acid Ethyl Ester 2-Bromo-3-methylbutyric Acid Ethyl Ester (CAS 609-12-1, molecular weight 209.08 g/mol), an active pharmaceutical ingredient.
• Butetamate-dihydrogencitrate (RS)-2-(Diethylamino)ethyl-2-phenylbutanoat (CAS 13900-12-4, molecular weight 455.51 g/mol), an API for respiratory applications.
• Chlorobutanol (anhydrous) 1,1,1-Trichloro-2-methyl-2-propanol (CAS 57-15-8, molecular weight 177.46 g/mol), used as a pharmaceutical preservative.
• Chlorobutanol (hemihydrate) 1,1,1-Trichloro-2-methyl-2-propanol hemihydrate (CAS 6001-64-5, molecular weight 186.46 g/mol), a pharmaceutical preservative.
• Menglytate Ethoxyacetic acid p-menth-3-yl ester (CAS 579-94-2, molecular weight 242.36 g/mol), an active pharmaceutical ingredient.
• Methantheline bromide (MTB) N,N-Diethyl-N-methyl-2-(9-xanthenecarbonyloxy)ethylammonium bromide (CAS 53-46-3, molecular weight 420.35 g/mol), an anticholinergic API.
• Sodium-DMPS 2,3-Dimercaptopropanesulfonic acid sodium salt (CAS 4076-02-2, molecular weight 228.27 g/mol monohydrate), a chelating agent used as an antidote.
• Propiverine-Hydrochloride 2,2-Diphenyl-2-(1-propoxy)-acetic acid-(1-methyl-piperid-4-yl) ester hydrochloride (CAS 54556-98-8, molecular weight 403.95 g/mol), an anticholinergic API for urological applications.
• Flavognost Diphenylboric acid-2-aminoethylester (CAS 524-95-8, molecular weight 225.10 g/mol), a proprietary specialty chemical reagent.
• Kalignost Sodium tetraphenylborate (CAS 143-66-8, molecular weight 342.22 g/mol), a proprietary specialty chemical reagent used for analytical purposes.
• Custom Synthesis Services Custom synthesis services for specialty chemicals and APIs under cGMP conditions, utilizing flexible multi-purpose production equipment capable of performing a wide range of chemical reactions including hazardous chemistries.
• Process Development and Optimization Optimization of established production processes and development of new synthesis routes from initial concept to final product, including scale-up from laboratory to production scale.
• Analytical Development Analytical services including impurity profiling, complex analytical development, impurity identification, and isolation of impurities, utilizing equipment such as Bruker mass spectrometers, ReactIR FTIR, and HPLC-DAD systems.
• Regulatory Services (Drug Master File Compilation) Compilation and submission of Drug Master Files (DMF) for API products to regulatory authorities in Europe, USA, Japan, Poland, Spain, Portugal, and other countries.
• Logistics Services Arrangement of goods transport with logistics partners, with APIs shipped under current GDP (Good Distribution Practice) guidelines.

Quantifiable outcome

• 70% reduction in organic solvent emissions after activated carbon adsorber replacement (2022)
• +4 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Potential OLED Display Materials Partner (unnamed)minorStrategic or Co-development Partner · 1 January 2021As of 2021, Laborchemie Apolda was in negotiations for a potential partnership to supply substances for the construction of OLED display screen elements that could be used in the next generation of TVs from major manufacturers. The partnership had not been finalized as of the reporting date.
• MERCK KGaAcoreStrategic or Co-development Partner · 1 January 2001Strategic alliance established in 2001 between Laborchemie Apolda and MERCK KGaA in the field of liquid crystals. Under this partnership, Laborchemie manufactured and supplied liquid crystal substances and intermediates for MERCK's display technology products. This was a significant co-development and supply relationship in the specialty chemicals sector.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Patheon (Thermo Fisher Scientific): Global CDMO inside Thermo Fisher offering API development, drug product, and clinical/commercial manufacturing at scale. Operates in the same small-molecule API space but as a broad incumbent with a much wider service portfolio than Laborchemie.
• WuXi STA (WuXi AppTec): Large global CDMO offering small-molecule API and drug product services across multiple sites. Overlaps with Laborchemie in custom synthesis and cGMP API production, but operates at much larger scale and across broader geographies.

Direct peers

• Recipharm: European CDMO providing API manufacturing, fill-finish, and development services across multiple regulated sites. Comparable to Laborchemie as a small-molecule API and contract manufacturing peer, though with a broader dosage-form portfolio.
• CordenPharma: Full-service CDMO offering small-molecule APIs, peptides, oligonucleotides, and highly potent compounds across multiple sites. Comparable as a cGMP API manufacturer serving global pharma with hazardous and HPAPI handling capabilities similar to those at Apolda.
• Aenova Group: German-headquartered CDMO with strong small-molecule API and finished dosage form manufacturing for pharma customers. Geographic and regulatory profile comparable to Laborchemie, with similar B2B contract manufacturing focus.
• Cambrex: Small-molecule API CDMO with custom development and manufacturing services, including controlled substances and HPAPIs. Closely comparable to Laborchemie's custom synthesis and API manufacturing model for global pharmaceutical customers.
• Siegfried Holding: Swiss-listed CDMO specializing in small-molecule API manufacturing, including regulated intermediates, custom synthesis, and sterile fill-finish. Comparable to Laborchemie in offering cGMP small-molecule API production for global pharmaceutical clients, though at materially larger scale.
• Hovione: Portugal-headquartered CDMO focused on small-molecule API development and manufacturing, including HPAPIs, particle engineering, and drug substance services. Directly comparable to Laborchemie's API manufacturing and hazardous-chemistry capabilities, with deeper HPAPI breadth.
• Haupt Pharma: German CDMO focused on small-batch solid, semi-solid, and liquid pharmaceutical manufacturing as well as sterile and API production. Comparable to Laborchemie in regulated contract manufacturing for European pharma customers, particularly in niche and orphan segments.

Regional players

• Caelo (Caesar & Loretz): German manufacturer and distributor of pharmaceutical raw materials, APIs, and specialty excipients. Adjacent rather than direct competition, but comparable as a German-based specialty pharmaceutical inputs producer serving compounding pharmacies and pharma manufacturers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/laborchemie
• LinkedInlinkedin.com/company/laborchemie-apolda-gmbh

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laboratory chemistry Apolda